ASCO Presentation: Diffusion Pharmaceuticals presented interim clinical data from a Phase 1/2 multi-center study of TSC in newly diagnosed glioblastoma at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

Data supporting the expanded clinical development of its novel hypoxia-targeted compound, TSC, was presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, June 1, 2015 at McCormick Place in Chicago. The poster presentation included 21 month interim data from the Company’s Phase I/II open label, multi-center trial testing the safety and efficacy of TSC delivered concurrently with standard-of-care radiation therapy and chemotherapy in 59 patients newly diagnosed with primary brain cancer (glioblastoma, or GBM). The poster, which was entitled “Use of a novel radio-sensitizer for treatment of GBM” was presented Monday, June 1, 2015, from 1:15 PM to 4:45 PM in McCormick Place.